All News

Pharmacists can guide patients in verifying sources, identifying licensed pharmacies, and understanding compounded vs FDA-approved products.

A new study found that first-prescription buprenorphine abandonment nearly doubled from 2020 to 2024.

A revamped weight management program adds transparent Zepbound and Foundayo pricing, $29 MinuteClinic visits, and pharmacist support at 9000 sites.

Phase 3 SOLARIS shows high-dose vitamin D3 with first-line chemo in metastatic colorectal cancer is safe—but does not significantly improve PFS.

The newly available OTC combination pairs dextromethorphan, guaifenesin, and naproxen sodium in a 12-hour formulation, creating new opportunities for pharmacist counseling on NSAID risks and duplicate therapy.

The therapy is administered via an intratumoral injection every 2 weeks for 8 consecutive doses.

Real-world data linked semaglutide use to reduced liver stiffness and improved liver outcomes, with some benefits occurring independently of weight loss.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses how pharmacists can layer mediator-symptom management with cytoreductive or targeted therapy in systemic mastocytosis (SM) and interdisciplinary communication.

Residency ranking often shifts from structured metrics to “fit” and vibes, risking bias toward familiarity; refocus decisions on evidence, values, and potential.

Reflections on the 2025-2026 AACP Argus Commission Forecast

In adults with alcohol use disorder and diabetes or obesity, semaglutide or tirzepatide lowered hospitalization risk across 4 target trial emulations.

Hannaford's Sara Lane, PharmD, shares how standardized workflows and a growing technician immunizer program have driven measurable gains in vaccination rates.

A review offering guidance to pharmacists on the importance of peer review as well as a tutorial on how to perform and respond to peer review.

Guest Jenelle Montgomery, PharmD, BCACP, CPP, joins Erica Marini to review key updates from the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

An investigational KRAS-targeted peptide vaccine generated durable immune responses and demonstrated early potential to intercept pancreatic cancer development in high-risk patients.

Orzeyful is the first orexin-restoring therapy for NT1, backed by the phase 3 FirstLight and RadiantLight trials.

Craig Beavers, PharmD, discusses a new American College of Cardiology expert consensus decision pathway that shifts HFpEF management from ejection fraction alone toward phenotype-driven diagnosis and treatment.

Schwartz must immediately address a measles crisis that has reached a 35-year high in the US, as well as a growing Cyclospora outbreak

This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

Pharmacists are well positioned to clear the confusion on treatments for menopause through evidence-based counseling and individualized symptom management.

The findings point to persistent vaccine hesitancy and access gaps in the years since the COVID-19 pandemic, with authors calling for stronger clinician recommendations and school-based vaccination sites.

In a phase 4 study, 90.9% of patients receiving preoperative suzetrigine-based multimodal therapy avoided opioid rescue after aesthetic or reconstructive surgery.

The future of 340B depends on integrating quality, compliance, technology, and pharmacist-led care to improve patient outcomes and strengthen audit readiness.

FDA-approved colorectal cancer blood tests—Shield, Epi proColon, SimpleScreen—expand blood-based screening, but positives still need colonoscopy.

Revumenib and ziftomenib in NPM1-mutated AML: practical guidance on differentiation syndrome, QTc monitoring, and drug interactions.

Zongertinib offers durable activity in HER2-mutant NSCLC while highlighting pharmacists’ essential role in biomarker verification, dosing, medication review, adherence, and toxicity management.

ASCO 2026 spotlights PROTEUS shifts, new breast cancer data, lung cancer treatment advances, and daxonrasib gains hope in pancreatic cancer.

A randomized trial found that medically tailored groceries cut hemoglobin A1C by 0.40 points and sharply improved food security in adults with type 2 diabetes.